ReviewFrontiers in oncology2025
Nanoparticle-ultrasound synergy: an emerging theranostic paradigm for breast and gynecologic cancers.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC), cervical cancer (CC), and ovarian cancer (OC) are among the most prevalent and life-threatening malignancies affecting women worldwide. While conventional therapies have improved patient outcomes, they often result in suboptimal survival and quality of life. In recent years, ultrasound (US) has emerged as a promising therapeutic tool, not only for its well-established role in diagnostic imaging but also for its safety, deep tissue penetration, and real-time capabilities. The integration of US with nanotechnology has further expanded its potential, enabling nanoparticles (NPs) to function as contrast agents, drug delivery vehicles, and energy mediators in cancer theranostics. This review explores the synergistic effects of NPs and US in the diagnosis and treatment of breast and gynecologic cancers, with a focus on OC and CC, while also including BC due to its clinical significance and shared imaging modalities. We examine the biophysical mechanisms underlying US-based therapies, the design of multifunctional nanoplatforms, and their applications in enhanced imaging, high-intensity focused ultrasound (HIFU), sonodynamic therapy (SDT), and US-triggered drug delivery. Finally, we discuss the translational challenges and future prospects of these innovative technologies, emphasizing their potential to transform the clinical management of BC, CC, and OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.